Investments in San Diego County startups decreased by 35% in the second quarter compared to a year ago, marking it the third ...

Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

For anyone who wants to understand Gilead Sciences' profit beyond the statutory numbers, it's important to note that during ...

Gilead Sciences delivered a breakout performance Friday, surging 8.3% to $119.41 in its strongest single-day gain in nearly ...

The S&P 500 added 0.8% on Friday, Aug. 8, 2025, finishing just short of the closing record it set last week. Gilead Sciences ...

U.S. stocks are drifting near their record heights as Wall Street waits for an upcoming update on inflation.

Patients with HIV who are resistant to all four antiretroviral drug classes face a higher risk for death than those who are ...

Gilead Sciences delivered a better-than-expected second quarter, propelled by the strong performance of its HIV portfolio and the launch of Yeztugo, its twice-yearly injectable for HIV prevention.

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Gilead Sciences (NASDAQ:GILD) and its peers.

Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 8.7% in the morning session after the company ...

Gilead Sciences ( NASDAQ: GILD) was upgraded to Buy from Hold at Truist after the company raised full year sales and profit ...

Legend Biotech announced its Q2 earnings, reporting $439m of revenues for its only commercial product, the cell therapy ...